AI Analysis

Log in to generate an AI summary for this stock.

Log in to generate a MOAT report for this stock.

Log in to generate an earnings report for this stock.

Log in to generate an operating leverage report for this stock.

Log in to generate a management report for this stock.

Log in to generate a valuation report for this stock.

Weave Communications, Inc.

$7.31 +$0.14 (+1.95%)
NYSE · 11 Sep 2026 20:00 UTC
Previous Close
$7.3
Day Range
$7.3$7.32
Year Range
$4.24$7.97
Market Cap
581.62M
AVG Volume
2.18M
Trailing/Forward PE
-28.85/29.54
PEG ratio
-0.63
Dividend Yield
-
Next Earnings Date
2026-11-04
Primary Exchange
New York Stock ExchangeUS
Revenue (USD)
0100M200M300M202020212022202320242025
WEAV Revenue (USD) by year
PeriodRevenue (USD)
2025239.02M
2024204.31M
2023170.47M
2022142.12M
2021115.87M
202080.79M
Net Income (USD)
-60M-40M-20M0202020212022202320242025
WEAV Net Income (USD) by year
PeriodNet Income (USD)
2025-28.05M
2024-28.35M
2023-31.03M
2022-49.74M
2021-51.69M
2020-37.2M
Operating Income (USD)
-60M-40M-20M0202020212022202320242025
WEAV Operating Income (USD) by year
PeriodOperating Income (USD)
2025-30.61M
2024-31.41M
2023-34.37M
2022-49.7M
2021-50.39M
2020-36.25M
EBITDA (USD)
-40M-30M-20M-10M0202020212022202320242025
WEAV EBITDA (USD) by year
PeriodEBITDA (USD)
2025-11.3M
2024-7.74M
2023-6.85M
2022-31.7M
2021-35.74M
2020-26.8M
Cash Flows (USD)
-40M-20M020M202020212022202320242025
WEAV Cash Flows (USD) by year
PeriodCash Flows (USD)
202515.15M
202410.78M
20236.53M
2022-15.89M
2021-30.18M
2020-18.47M
EPS (USD)
-2-1.5-1-0.50202020212022202320242025
WEAV EPS (USD) by year
PeriodEPS (USD)
2025-0.36
2024-0.39
2023-0.45
2022-0.76
2021-0.98
2020-1.97
Expenses (USD)
0100M200M300MR&DSG&ACapex202020212022202320242025
WEAV Expenses (USD) by year
PeriodExpenses (USD)
2025205.31M
2024180.67M
2023154.15M
2022141.67M
2021126.7M
202085.08M
Cash & Debt (USD)
050M100M150MCashLong Term DebtShort Term Debt202020212022202320242025
WEAV Cash & Debt (USD) by year
PeriodCash & Debt (USD)
202581.72M
202499.13M
2023108.84M
2022113.34M
2021136M
202055.7M
Debt ratios
00.20.40.6202320242025
WEAV Debt ratios by year
PeriodDebt ratios
20250.51
20240.53
20230.49
Margins
0%20%40%60%80%202020212022202320242025
WEAV Margins by year
PeriodMargins
202572.09%
202471.4%
202368.1%
202262.51%
202157.39%
202056.79%
Return on Capital
-100%-75%-50%-25%0%202020212022202320242025
WEAV Return on Capital by year
PeriodReturn on Capital
2025-34.05%
2024-42.33%
2023-39.3%
2022-59.77%
2021-46.03%
2020-97.91%
Shares Outstanding
020M40M60M80M202020212022202320242025
WEAV Shares Outstanding by year
PeriodShares Outstanding
202578.15M
202472.86M
202369.72M
202265.63M
202163.62M
202056.54M
Book Value Per Share (USD)
00.511.52202020212022202320242025
WEAV Book Value Per Share (USD) by year
PeriodBook Value Per Share (USD)
20251.05
20240.92
20231.13
20221.27
20211.77
20200.67
Total Assets (USD)
0100M200M300M202020212022202320242025
WEAV Total Assets (USD) by year
PeriodTotal Assets (USD)
2025207.97M
2024188.93M
2023201.01M
2022208.35M
2021187.49M
202092.97M
Employee Count
02505007501K20212022202320242025
WEAV Employee Count by year
PeriodEmployee Count
2025904
2024854
2023844
2022806
2021889
Free Cash Flow Yield
0%2%4%6%8%med 2.48%Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
WEAV Free Cash Flow Yield by year
PeriodFree Cash Flow Yield
Sep 262.46%
Sep 262.45%
Aug 262.46%
Aug 262.46%
Aug 263.29%
Aug 263.39%
Jul 261.87%
Jul 261.98%
Jul 261.69%
Jul 261.76%
Jul 261.85%
Jun 262.06%
Jun 262.35%
Jun 262.21%
Jun 262.14%
May 262.03%
May 262.14%
May 262.31%
May 262.05%
May 263.37%
Apr 263.98%
Apr 263.64%
Apr 264.19%
Apr 263.95%
Mar 264.44%
Mar 264.08%
Mar 263.97%
Mar 263.49%
Feb 264.23%
Feb 263.94%
Feb 263.81%
Feb 263.41%
Jan 263.28%
Jan 263.12%
Jan 263.21%
Jan 262.98%
Jan 262.98%
Dec 252.98%
Dec 253.08%
Dec 253.04%
Dec 253.31%
Nov 253.35%
Nov 253.57%
Nov 253.49%
Nov 253.34%
Oct 252.58%
Oct 252.76%
Oct 252.96%
Oct 252.91%
Oct 252.88%
Sep 252.69%
Sep 252.51%
Sep 252.49%
Sep 252.47%
Aug 252.46%
Aug 252.47%
Aug 252.46%
Aug 252.53%
Aug 256.08%
Jul 255.36%
Jul 255.34%
Jul 255.36%
Jul 254.72%
Jun 255.04%
Jun 255.1%
Jun 254.87%
Jun 254.19%
May 254.3%
May 254.33%
May 253.85%
May 253.98%
May 251.37%
Apr 251.42%
Apr 251.59%
Apr 251.55%
Apr 251.57%
Mar 251.34%
Mar 251.26%
Mar 251.32%
Mar 250.92%
Feb 250.84%
Feb 250.74%
Feb 250.61%
Feb 250.61%
Jan 250.65%
Jan 250.65%
Jan 250.67%
Jan 250.68%
Jan 250.66%
Dec 240.65%
Dec 240.65%
Dec 240.68%
Dec 240.72%
Nov 240.77%
Nov 240.76%
Nov 240.79%
Nov 240.74%
Nov 240.61%
Oct 240.59%
Oct 240.59%
Price to Sales
02468med 2.39Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
WEAV Price to Sales by year
PeriodPrice to Sales
Sep 262.26
Sep 262.26
Aug 262.25
Aug 262.25
Aug 261.69
Aug 261.63
Jul 262.07
Jul 261.95
Jul 262.28
Jul 262.19
Jul 262.08
Jun 261.87
Jun 261.64
Jun 261.74
Jun 261.8
May 261.9
May 261.8
May 261.67
May 261.88
May 261.88
Apr 261.59
Apr 261.74
Apr 261.51
Apr 261.61
Mar 261.43
Mar 261.55
Mar 261.6
Mar 261.82
Feb 261.66
Feb 261.79
Feb 261.84
Feb 262.06
Jan 262.14
Jan 262.25
Jan 262.19
Jan 262.36
Jan 262.36
Dec 252.36
Dec 252.28
Dec 252.31
Dec 252.12
Nov 252.1
Nov 251.97
Nov 252.02
Nov 252.1
Oct 252.51
Oct 252.35
Oct 252.19
Oct 252.23
Oct 252.25
Sep 252.41
Sep 252.58
Sep 252.6
Sep 252.63
Aug 252.64
Aug 252.63
Aug 252.64
Aug 252.57
Aug 252.37
Jul 252.68
Jul 252.69
Jul 252.68
Jul 253.05
Jun 252.85
Jun 252.82
Jun 252.96
Jun 253.43
May 253.34
May 253.32
May 253.74
May 253.61
May 253.85
Apr 253.72
Apr 253.32
Apr 253.4
Apr 253.36
Mar 253.93
Mar 254.17
Mar 253.99
Mar 254.21
Feb 254.63
Feb 255.24
Feb 256.39
Feb 256.33
Jan 256
Jan 255.96
Jan 255.79
Jan 255.72
Jan 255.86
Dec 245.93
Dec 245.93
Dec 245.68
Dec 245.4
Nov 245.03
Nov 245.11
Nov 244.88
Nov 245.21
Nov 245
Oct 245.14
Oct 245.15
EV/EBITDA
100120140160180med 165.35Aug 26Aug 26Aug 26Aug 26Sep 26Sep 26
WEAV EV/EBITDA by year
PeriodEV/EBITDA
Sep 26165.83
Sep 26166.3
Aug 26165.35
Aug 26165.35
Aug 26121.81
Aug 26117.77
Price/Operating Cashflow
0255075100125med 34.45Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
WEAV Price/Operating Cashflow by year
PeriodPrice/Operating Cashflow
Sep 2634.55
Sep 2634.64
Aug 2634.45
Aug 2634.45
Aug 2625.8
Aug 2625
Jul 2642.63
Jul 2640.22
Jul 2647.13
Jul 2645.18
Jul 2642.89
Jun 2638.59
Jun 2633.9
Jun 2635.98
Jun 2637.09
May 2639.24
May 2637.22
May 2634.42
May 2638.72
May 2625.62
Apr 2621.7
Apr 2623.75
Apr 2620.63
Apr 2621.88
Mar 2619.47
Mar 2621.16
Mar 2621.74
Mar 2624.77
Feb 2621.23
Feb 2622.83
Feb 2623.59
Feb 2626.32
Jan 2627.38
Jan 2628.77
Jan 2628.01
Jan 2630.2
Jan 2630.2
Dec 2530.16
Dec 2529.19
Dec 2529.53
Dec 2527.13
Nov 2526.87
Nov 2525.15
Nov 2525.78
Nov 2526.91
Oct 2533.81
Oct 2531.62
Oct 2529.48
Oct 2530.02
Oct 2530.34
Sep 2532.49
Sep 2534.72
Sep 2535
Sep 2535.36
Aug 2535.5
Aug 2535.41
Aug 2535.54
Aug 2534.54
Aug 2514.99
Jul 2516.99
Jul 2517.05
Jul 2516.99
Jul 2519.29
Jun 2518.06
Jun 2517.84
Jun 2518.72
Jun 2521.75
May 2521.18
May 2521.05
May 2523.66
May 2522.89
May 2555.61
Apr 2553.71
Apr 2547.94
Apr 2549.12
Apr 2548.46
Mar 2556.69
Mar 2560.25
Mar 2557.67
Mar 2573.5
Feb 2580.89
Feb 2591.54
Feb 25111.57
Feb 25110.48
Jan 25104.77
Jan 25104
Jan 25101.11
Jan 2599.82
Jan 25102.39
Dec 24103.48
Dec 24103.48
Dec 2499.25
Dec 2494.3
Nov 2487.76
Nov 2489.3
Nov 2485.19
Nov 2491.03
Nov 2493.06
Oct 2495.54
Oct 2495.76
Price to Book
05101520med 6.97Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
WEAV Price to Book by year
PeriodPrice to Book
Sep 266.85
Sep 266.87
Aug 266.83
Aug 266.83
Aug 265.12
Aug 264.96
Jul 266.17
Jul 265.82
Jul 266.82
Jul 266.54
Jul 266.21
Jun 265.59
Jun 264.91
Jun 265.21
Jun 265.37
May 265.68
May 265.39
May 264.98
May 265.6
May 265.45
Apr 264.62
Apr 265.06
Apr 264.39
Apr 264.66
Mar 264.15
Mar 264.51
Mar 264.63
Mar 265.27
Feb 264.85
Feb 265.22
Feb 265.39
Feb 266.02
Jan 266.26
Jan 266.58
Jan 266.4
Jan 266.9
Jan 266.9
Dec 256.89
Dec 256.67
Dec 256.75
Dec 256.2
Nov 256.14
Nov 255.75
Nov 255.89
Nov 256.15
Oct 257.03
Oct 256.57
Oct 256.13
Oct 256.24
Oct 256.31
Sep 256.75
Sep 257.22
Sep 257.28
Sep 257.35
Aug 257.38
Aug 257.36
Aug 257.39
Aug 257.18
Aug 257.35
Jul 258.33
Jul 258.36
Jul 258.33
Jul 259.46
Jun 258.86
Jun 258.75
Jun 259.18
Jun 2510.67
May 2510.39
May 2510.32
May 2511.6
May 2511.22
May 2511.75
Apr 2511.35
Apr 2510.13
Apr 2510.38
Apr 2510.24
Mar 2511.98
Mar 2512.73
Mar 2512.19
Mar 2511.98
Feb 2513.18
Feb 2514.92
Feb 2518.18
Feb 2518
Jan 2517.07
Jan 2516.95
Jan 2516.48
Jan 2516.27
Jan 2516.68
Dec 2416.86
Dec 2416.86
Dec 2416.17
Dec 2415.37
Nov 2414.3
Nov 2414.55
Nov 2413.88
Nov 2414.83
Nov 2413.4
Oct 2413.75
Oct 2413.78
Weave Communications, Inc.
WEAV
Stockpicker

Video analysis: WEAV

All videos

No video analysis for this stock yet. Request one from our team.

Your email is used only to follow up on this request. We do not add you to marketing lists. Privacy Policy

News: WEAV

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Centerspace (NYSE – CSR), Fulcrum Therapeutics, Inc. (Nasdaq – FULC), Weave Communications, Inc. (NYSE – WEAV), Bio-Techne Corporation (Nasdaq – TECH)

globenewswire.com · 9 Sep 2026

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Centerspace (NYSE – CSR), Fulcrum Therapeutics, Inc. (Nasdaq – FULC), Weave Communications, Inc. (NYSE – WEAV), Bio-Techne Corporation (Nasdaq – TECH)

BALA CYNWYD, Pa., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.

Weave Bio Announces Collaboration with Takeda to Deploy AI-Native Regulatory Automation Across Key Drug Development Activities

businesswire.com · 1 Sep 2026

Weave Bio Announces Collaboration with Takeda to Deploy AI-Native Regulatory Automation Across Key Drug Development Activities

SAN FRANCISCO--(BUSINESS WIRE)-- #AI--Weave Bio, the leader in AI-native regulatory automation for drug development, today announced a collaboration with Takeda to deploy the Weave platform across 14 active programs in multiple global markets. The collaboration brings together Weave's AI capabilities and Takeda's regulatory expertise to support innovation in regulatory workflows. “Regulatory communications are the most knowledge-intensive workflows in all of drug development, and for too long that kn.

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Fulcrum Therapeutics, Inc. (Nasdaq – FULC), Weave Communications, Inc. (NYSE – WEAV), Iridium Communications Inc. (Nasdaq – IRDM), Bio-Techne Corporation (Nasdaq – TECH)

globenewswire.com · 24 Aug 2026

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Fulcrum Therapeutics, Inc. (Nasdaq – FULC), Weave Communications, Inc. (NYSE – WEAV), Iridium Communications Inc. (Nasdaq – IRDM), Bio-Techne Corporation (Nasdaq – TECH)

BALA CYNWYD, Pa., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.

$HAREHOLDER ALERT: The M&A Class Action Firm Announce the Investigation of the Merger - WEAV, BRBS, TDAC and UHG

gurufocus.com · 23 Aug 2026

$HAREHOLDER ALERT: The M&A Class Action Firm Announce the Investigation of the Merger - WEAV, BRBS, TDAC and UHG

$HAREHOLDER ALERT: The M&A Class Action Firm Announce the Investigation of the Merger - WEAV, BRBS, TDAC and UHG PR Newswire

Weave Communications Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Weave Communications, Inc. - WEAV

businesswire.com · 21 Aug 2026

Weave Communications Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Weave Communications, Inc. - WEAV

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Weave Communications, Inc. (NYSE: WEAV) to Francisco Partners. Under the terms of the proposed transaction, shareholders of Weave will receive $7.40 in cash for each share of Weave that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate,.

Weave's 2026 Pulse Survey Finds Healthcare Practices Are Ready for AI, but 60% Are Still Concerned About Data Privacy

businesswire.com · 20 Aug 2026

Weave's 2026 Pulse Survey Finds Healthcare Practices Are Ready for AI, but 60% Are Still Concerned About Data Privacy

LEHI, Utah--(BUSINESS WIRE)-- #getweave--Weave (NYSE: WEAV), a leading AI-powered patient engagement and payments platform purpose-built for healthcare practices, today released its 2026 State of Healthcare Pulse Survey, a survey of 285 owners, office managers, and front desk staff across dental, specialty medical, optometry, and veterinary practices. The findings point to a clear consensus: manual administrative work in disconnected systems is the biggest drag on healthcare practices, and interest in AI i.

Halper Sadeh LLC is Investigating Whether WEAV and FULC are Obtaining Fair Deals for their Shareholders

globenewswire.com · 19 Aug 2026

Halper Sadeh LLC is Investigating Whether WEAV and FULC are Obtaining Fair Deals for their Shareholders

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

Shareholder Alert: Ademi LLP investigates whether Weave Communications, Inc. is obtaining a Fair Price for Public Shareholders

gurufocus.com · 19 Aug 2026

Shareholder Alert: Ademi LLP investigates whether Weave Communications, Inc. is obtaining a Fair Price for Public Shareholders

Shareholder Alert: Ademi LLP investigates whether Weave Communications, Inc. is obtaining a Fair Price for Public Shareholders PR

Similar companies

Disclaimer: The historical data presented on this platform is provided by Financial Modeling Prep. Stock Picker is a platform for informational purposes only and does not provide financial advice. Users are encouraged to conduct their own research and consult with a qualified financial advisor before making investment decisions.